Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trial

被引:65
|
作者
Lertrit, Amornpan [1 ]
Srimachai, Sasinee [1 ]
Saetung, Sunee [1 ]
Chanprasertyothin, Suwannee [2 ]
Chailurkit, La-or [1 ]
Areevut, Chatvara [1 ]
Katekao, Pornalat [3 ]
Ongphiphadhanakul, Boonsong [1 ]
Sriphrapradang, Chutintorn [1 ]
机构
[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Med, Bangkok, Thailand
[2] Mahidol Univ, Ramathibodi Hosp, Res Ctr, Fac Med, Bangkok, Thailand
[3] Mahidol Univ, Ramathibodi Hosp, Pharm Div, Fac Med, Bangkok, Thailand
关键词
Artificial sweeteners; Diabetes mellitus; Glucagon-like peptide 1; Insulin secretion; Insulin sensitivity; Non-nutritive sweeteners; Sucralose; TYPE-2; DIABETES-MELLITUS; ORAL GLUCOSE-TOLERANCE; DIET SODA INTAKE; ARTIFICIAL SWEETENERS; HORMONAL RESPONSES; TASTE RECEPTORS; UNITED-STATES; WEIGHT-GAIN; BODY-WEIGHT; CONSUMPTION;
D O I
10.1016/j.nut.2018.04.001
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objectives: Emerging evidence shows that non-nutritive sweeteners might induce glucose intolerance. This study aims to determine the effects of chronic exposure to sucralose on glycemic response, insulin secretion and sensitivity, and glucagon-like peptide-1 (GLP-1) release in healthy subjects. Methods: Healthy volunteers who did not use non-nutritive sweeteners and were normoglycemia after oral glucose tolerance test (OGTT) were recruited. Subjects underwent a 75-g OGIT on two separate occasions, preceded by blindly consuming pills containing either 200 mg sucralose or placebo for 4 wk in a randomized crossover trial. Plasma glucose, insulin, and active GLP-1 levels were obtained after ingesting 75-g glucose. On the following day, intravenous glucose tolerance test (IVGIT) was performed to evaluate the acute insulin response (AIR). Results: Fifteen participants (11 females, age 31.9 +/- 10 y, body mass index 23.1 3 kg/m(2)) participated in the study. AIR was lower after exposure to sucralose than placebo (58.9 +/- 48.61 versus 69.94 +/- 73.81 mu U/mL, P <0.001). Whole-body insulin sensitivity (estimated using the Matsuda index) was lower in sucralose than placebo (4.69 +/- 1.67 versus 5.31 +/- 2.56, P < 0.005). AUC of active GLP-1 was significantly higher in the sucralose than placebo (23.16 +/- 18.86 versus 18.5 +/- 22.22 pmol/L 120 min, P < 0.001). Conclusions: The continuous exposure to sucralose reduced AIR, decreased insulin sensitivity, and enhanced GLP-1 release in healthy subjects. However, the clinical significance of these results needs to be investigated in longer follow-up studies. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:125 / 130
页数:6
相关论文
共 50 条
  • [31] Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
    Nino, Antonio
    Okuda, Inaha
    Wilson, Timothy H.
    Yue, Lynn
    Nakajima, Hiromu
    Tsuboi, Maho
    Carr, Molly C.
    Seino, Yutaka
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (03): : 558 - 566
  • [32] The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
    Umpierrez, G. E.
    Blevins, T.
    Rosenstock, J.
    Cheng, C.
    Anderson, J. H.
    Bastyr, E. J., III
    DIABETES OBESITY & METABOLISM, 2011, 13 (05): : 418 - 425
  • [33] Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial
    Roshanravan, Neda
    Mahdavi, Reza
    Alizadeh, Effat
    Jafarabadi, Mohammad Asghari
    Hedayati, Mehdi
    Ghavami, Abed
    Alipour, Shahriar
    Alamdari, Naimeh Mesri
    Barati, Meisam
    Ostadrahimi, Alireza
    HORMONE AND METABOLIC RESEARCH, 2017, 49 (11) : 886 - 891
  • [34] Cognitive effects of pregabalin in healthy volunteers A double-blind, placebo-controlled trial
    Salinsky, Martin
    Storzbach, Daniel
    Munoz, Sonia
    NEUROLOGY, 2010, 74 (09) : 755 - 761
  • [35] Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
    Bojer, Annemie Stege
    Sorensen, Martin Heyn
    Bjerre, Jenny
    Gaede, Peter
    Vejlstrup, Niels
    Madsen, Per Lav
    DIABETES OBESITY & METABOLISM, 2021, 23 (10): : 2374 - 2384
  • [36] Effects of endogenous glucagon-like peptide-1 on gastric emptying in healthy subjects - relationship to glycaemia
    Deane, A. M.
    Nguyen, N. Q.
    Stevens, J. E.
    Fraser, R. J. L.
    Holloway, R. H.
    Jones, K. L.
    Besanko, L. K.
    Burgstad, C.
    Summers, M.
    Zaknic, A.
    Chapman, M. J.
    Horowitz, M.
    DIABETOLOGIA, 2009, 52 : S311 - S312
  • [37] Effects of Methylphenidate on Fatigue and Depression: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kerr, Christopher W.
    Drake, Julie
    Milch, Robert A.
    Brazeau, Daniel A.
    Skretny, Judith A.
    Brazeau, Gayle A.
    Donnelly, James P.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2012, 43 (01) : 68 - 77
  • [38] Arterial effects of acupuncture in migraine: A randomized, double-blind, placebo-controlled trial
    Boutouyrie, P
    Laloux, B
    Corvisier, R
    Vulser, C
    Girard, A
    Laurent, S
    HYPERTENSION, 2005, 46 (04) : 897 - 897
  • [39] Marfan Sartan: a randomized, double-blind, placebo-controlled trial
    Milleron, Olivier
    Arnoult, Florence
    Ropers, Jacques
    Aegerter, Philippe
    Detaint, Delphine
    Delorme, Gabriel
    Attias, David
    Tubach, Florence
    Dupuis-Girod, Sophie
    Plauchu, Henry
    Barthelet, Martine
    Sassolas, Francois
    Pangaud, Nicolas
    Naudion, Sophie
    Thomas-Chabaneix, Julie
    Dulac, Yves
    Edouard, Thomas
    Wolf, Jean-Eric
    Faivre, Laurence
    Odent, Sylvie
    Basquin, Adeline
    Habib, Gilbert
    Collignon, Patrick
    Boileau, Catherine
    Jondeau, Guillaume
    EUROPEAN HEART JOURNAL, 2015, 36 (32) : 2160 - U37
  • [40] A double-blind, randomized, placebo-controlled laser trial methodology
    Oussedik, E.
    Saleem, M. D.
    Patel, N. U.
    Feldman, S. R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : B11 - B11